Literature DB >> 15754583

Transthoracic or transhiatal resection for middle- and lower-third esophageal carcinoma?

Shah-Hwa Chou1, Eing-Long Kao, Hung-Yi Chuang, Wen-Ming Wang, Deng-Chyang Wu, Meei-Feng Huang.   

Abstract

Transthoracic esophagectomy (TTE) and transhiatal esophagectomy (THE) are two common methods of resection for esophageal cancer. Although many studies have been performed in Western countries, there are still controversies over which method is the better procedure. In this study, postoperative improvement in dysphagia and the degree of postoperative pain were compared. The cases of 50 patients undergoing TTE and 23 undergoing THE for esophageal cancer between March 1997 and October 2002 were retrospectively reviewed. The location of the lesion, clinical stage (TNM), operative time, operative blood loss, hospital stay, complications, number of lymph nodes dissected, and survival duration were recorded. Pre- and postoperative dysphagia scores and postoperative pain perception (using a visual analog scale) were analyzed. Preoperative clinical stage and lesion site were not significantly different in the TTE and THE groups. The operative time was longer and the number of lymph nodes removed was larger in the TTE group. However, there were no differences in operative blood loss, hospital stay, complications, survival duration, and improvement in dysphagia. Pain perception in the THE group was significantly better than that in the TTE group. THE is a safe and rapid procedure, with recovery and survival periods similar to those for TTE. Both patient groups enjoyed the same ability to eat. Therefore, THE is an acceptable alternative to TTE for patients with middle- and lower-third esophageal cancer. Moreover, THE caused much less postoperative pain than TTE, which made patients more comfortable.

Entities:  

Mesh:

Year:  2005        PMID: 15754583     DOI: 10.1016/S1607-551X(09)70270-0

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  6 in total

Review 1.  Transthoracic vs transhiatal surgery for cancer of the esophagogastric junction: a meta-analysis.

Authors:  Ming-Tian Wei; Yuan-Chuan Zhang; Xiang-Bing Deng; Ting-Han Yang; Ya-Zhou He; Zi-Qiang Wang
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

2.  Radical resection or chemoradiotherapy for cervical esophageal cancer?

Authors:  Shah-Hwa Chou; Hsien-Pin Li; Jui-Ying Lee; Meei-Feng Huang; Chia-Hua Lee; Ka-Wo Lee
Journal:  World J Surg       Date:  2010-08       Impact factor: 3.352

3.  Surgical Strategies for Siewert Type II Esophagogastric Junction Carcinomas: A Randomized Controlled Trial.

Authors:  Kai Tao; Jianhong Dong; Songbing He; Yingying Xu; Fan Yang; Guolin Han; Masanobu Abe; Liang Zong
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

4.  Transthoracic versus abdominal-transhiatal resection for treating Siewert type II/III adenocarcinoma of the esophagogastric junction: a meta-analysis.

Authors:  Zhi Zheng; Jun Cai; Jie Yin; Jun Zhang; Zhong-Tao Zhang; Kang-Li Wang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

5.  Nomogram predicted survival of patients with adenocarcinoma of esophagogastric junction.

Authors:  Zhangjian Zhou; Hao Zhang; Zisen Xu; Wenhan Li; Chengxue Dang; Yongchun Song
Journal:  World J Surg Oncol       Date:  2015-06-10       Impact factor: 2.754

6.  Proximal Gastrectomy versus Total Gastrectomy for Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Comprehensive Analysis of Data from the SEER Registry.

Authors:  Kaixuan Zhu; Yingying Xu; Jiaxin Fu; Farah Abdidahir Mohamud; Zongkui Duan; Siyuan Tan; Zekun Zhao; Ping Chen; Liang Zong
Journal:  Dis Markers       Date:  2019-12-31       Impact factor: 3.434

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.